Status:
COMPLETED
Nebulized Resveratrol Plus Carboxymethyl-β-Glucan for Reducing IL-5 in Children With Allergic Rhinitis
Lead Sponsor:
Istituto per la Ricerca e l'Innovazione Biomedica
Conditions:
Allergic Rhinitis
Eligibility:
All Genders
6-16 years
Phase:
PHASE4
Brief Summary
Single-center, randomized, placebo-controlled study to: * characterize the subjects at baseline and discriminate groups of children based on IL-5, IL-17, IL-23 and INF-γ; * investigate the effect of ...
Eligibility Criteria
Inclusion
- history of AR in the previous year;
- positive skin prick test to seasonal allergens.
Exclusion
- acute upper respiratory infections in the last 4 weeks;
- lifetime history of asthma (doctor diagnosis);
- use of nasal or oral corticosteroids, nasal or oral decongestants, antihistamines in the last 4 weeks;
- anatomic nasal defects (ie, septum deviation), or nasal polyps;
- active smoker.
Key Trial Info
Start Date :
March 5 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2018
Estimated Enrollment :
88 Patients enrolled
Trial Details
Trial ID
NCT03349619
Start Date
March 5 2018
End Date
July 31 2018
Last Update
December 5 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Biomedicine and Molecular Immunology (IBIM) - National Research Council of Palermo
Palermo, Italy, 90146